^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    IDH wild-type

    i
    Other names: HEL-216, HEL-S-26, Epididymis Luminal Protein 216, Isocitrate Dehydrogenase 1 (NADP+), Epididymis Secretory Protein Li 26, IDH1, Isocitrate Dehydrogenase (NADP(+)) 1, Isocitrate Dehydrogenase 1 (NADP+), Soluble, IDH2, Isocitrate Dehydrogenase (NADP(+)) 2, Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial, Isocitrate Dehydrogenase 2 (NADP+), Mitochondrial, Isocitrate Dehydrogenase [NADP], Mitochondrial, Oxalosuccinate Decarboxylase, NADP(+)-Specific ICDH, ICD-M, IDH, IDP, MNADP-IDH, D2HGA2, IDHM, IDPM
    Entrez ID:
    3417; 3418
    Related biomarkers:
    Expression
    Mutation
    Others
    1m
    Isocitrate Dehydrogenase-1 Mutation Status and Dynamic Subcortical Motor Mapping Using Ultrasonic Aspirator Stimulation. (PubMed, Oper Neurosurg)
    The interpretability of distance-based subcortical motor mapping is influenced by IDH1 mutation status, whereas continuous CUSA stimulation and ball-tip stimulation show comparable overall distance-threshold behavior. Distance-based scMEP thresholds are more reliable in IDH1-mutant tumors, whereas increased variability in IDH1-wildtype tumors likely reflects greater susceptibility to intraoperative brain shift and other biological factors, supporting a biologically informed, real-time electrophysiological approach in motor-eloquent tumor resections.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation • IDH wild-type
    1m
    QUILT-3.078: N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P2, N=34, Active, not recruiting, ImmunityBio, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    PD-L1 (Programmed death ligand 1)
    |
    IDH wild-type
    |
    Avastin (bevacizumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK
    1m
    E3 ligase LMO7 promotes ALKBH2 ubiquitination to sensitize MGMT-deficient glioblastoma to temozolomide. (PubMed, Cell Death Dis)
    High ALKBH2 expression in chemotherapy-treated IDH-wild-type glioma and low LMO7 expression in the CGGA astrocytoma cohort are each associated with shorter overall survival. Together, these results indicate that oxidative stress-coupled LMO7-dependent polyubiquitination of ALKBH2 modulates TMZ sensitivity in GBM, particularly in MGMT-deficient tumors.
    Journal
    |
    LMO7 (LIM Domain 7) • ALKBH2 (AlkB Homolog 2)
    |
    IDH wild-type
    |
    temozolomide
    1m
    CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma (clinicaltrials.gov)
    P1, N=1, Terminated, Chimeric Therapeutics | N=42 --> 1 | Trial completion date: Jan 2041 --> May 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2026 --> Apr 2026; IND application withdrawn
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    MMP2 (Matrix metallopeptidase 2)
    |
    IDH wild-type
    |
    CHM 1101
    1m
    IL1B-Expressing Exhausted CD4+ T Cells Are Associated With Disease Aggressiveness in Glioblastoma. (PubMed, Cancer Genomics Proteomics)
    CD4+ T cells are recruited to GBM tumors preferentially via the CCL5-CCR1/CCR5 axis, where their exhaustion-related IL1B upregulation along disease progression aligns with mesenchymal reprogramming that hallmarks disease aggressiveness in IDH-wildtype GBM.
    Journal
    |
    CD4 (CD4 Molecule) • IL1B (Interleukin 1, beta) • IL1R1 (Interleukin 1 receptor, type I)
    |
    IDH wild-type
    1m
    Tofacitinib in Recurrent GBM Patients (clinicaltrials.gov)
    P3, N=18, Completed, University of Texas Southwestern Medical Center | Active, not recruiting --> Completed | Trial completion date: Jun 2027 --> Oct 2025
    Trial completion • Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    EGFR amplification • IDH wild-type
    |
    temozolomide • lomustine • tofacitinib
    1m
    Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH1 R132 • IDH wild-type
    |
    temozolomide • peposertib (M3814)
    1m
    Photodynamic diagnosis using 5-aminolevulinic acid in surgery for spinal cord astrocytic tumors: a propensity score-matched comparison with brain tumors. (PubMed, J Neurosurg Spine)
    The findings of this study suggest that PDD may be less effective in the surgery of astrocytic tumors of the spinal cord compared with those of the brain. Verifying the molecular differences of astrocytic tumors between the spinal cord and brain in a large number of cases will be necessary in future studies.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH wild-type
    1m
    ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Institute of Cancer Research, United Kingdom | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TERT (Telomerase Reverse Transcriptase)
    |
    HER-2 positive • ER positive • HER-2 negative • EGFR amplification • IDH wild-type • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    Keytruda (pembrolizumab) • tolinapant (ASTX660)
    1m
    Structural remodeling of tumor microtubes in IDH1 mutation shapes microRNA transfer in glioma. (PubMed, Neurobiol Dis)
    In contrast, miR-340 was downregulated in glioma cells, and its direct transfection markedly inhibited proliferation without astrocyte toxicity; fluorescent miR-340 was also detected within TMs and recipient glioma cells. Together, these findings identify TMs as structural features shaped by IDH1 mutation and as conduits for intercellular exchange of both oncogenic and tumor-suppressive microRNAs, providing a framework for understanding TM-mediated communication and its potential therapeutic exploitation in glioma.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • MIR21 (MicroRNA 21) • CASP3 (Caspase 3) • CASP7 (Caspase 7) • MIR340 (MicroRNA 340)
    |
    IDH1 mutation • IDH1 R132 • IDH wild-type
    1m
    A novel glioma prognosis marker CAMK2A is related to immune microenvironment and may be involved in Ras/Raf/MEK/ERK signaling. (PubMed, Sci Rep)
    CAMK2A regulates glioma cell proliferation through the Ras/Raf/MEK/ERK signaling pathway. CAMK2A is a potentially important target for glioma therapy.
    Journal
    |
    CAMK2A (Calcium/Calmodulin Dependent Protein Kinase II Alpha)
    |
    IDH wild-type
    2ms
    Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas (clinicaltrials.gov)
    P1/2, N=33, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH wild-type
    |
    Zynyz (retifanlimab-dlwr)